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Poster Session I S251of survival at 5 years without requiring HSCT was only 28.11/-
8.8%.We conclude that only a minority of patients with CBF leuke-
mia will be long term survivors relying exclusively on conventional
chemotherapy. Early use of HSCT for high-risk CBF-AML should
be pursued in clinical trials.266
COMPARISON OF CONDITIONING REGIMENS BU-CY AND FLU-BU12-TG
USED IN THE PATIENTS UNDERGOING ALLOGENEIC STEM CELL
TRANSPLANTATION (SCT) FOR ACUTE MYELOID LEUKEMIA (AML)
Raida, L.1, Tucek, P.2, Vondrakova, J.1, Rusinakova, Z.1, Faber, E.1,
Indrak, K.1 1University Hospital, Olomouc, Czech Republic; 2Faculty of
Science, Olomouc, Czech Republic
Introduction: Standard myeloablative conditioning combined bu-
sulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) (BU-CY)
is associated with high non-hematologic toxicity, significantmorbid-
ity and mortality. Regimen combined fludarabin (125 mg/m2), bu-
sulphan (12 mg/kg) and thymoglobuline (6 mg/kg) (FLU-BU12-
TG) might be less toxic and safer despite the myeloablative dose of
busulphan. Retrospective study compared the results of allogeneic
SCT after those two regimens in the patients with AML.
Patients andMethods: 21 patients with AMLwere allografted after
BU-CY and 10 ones after FLU-BU12-TG. There were no differ-
ences between those groups in: the number of patients allografted
in complete remission of AML, gender and age of patients and do-
nors, the quality of graft and follow-up period. Significantly more
patients in the group of FLU-BU12-TG were allografted from un-
related (90% vs. 19%; P0,00018) and HLA mismatched donor
(50% vs. 0%; P0,0004). The incidence and risk of acute and chronic
graft versus host disease (GVHD), AML relapse, non-relapse
(NRM) and overall mortality, the probability of event-free (EFS)
and overall survival (OS) were analysed and compared in both con-
ditioning groups.
Results:No significant differences were found between the BU-CY
and FLU-BU12-TG in the incidence of acute (38% vs. 50%; P0,53)
or chronic GVHD (44% vs. 33%; P0,58), AML relapse (24% vs.
11%; P0,43), NRM (33% vs. 10%; P0,17), overall mortality (52%
vs. 20%; P0,087), the probability of 2-year EFS (50% vs. 89%;
P0,19) and OS (55% vs. 80%; P0,28).
Conclusion: Regimen FLU-BU12-TG seems to be a feasible
alternative approach to the patients allografted for AML and requir-
ing pretransplant cytoreduction but standard myeloablative condi-
tioning would be associated with the significant risk of severe
complications.LYMPHOMA/MULTIPLE MYELOMA
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MAINTENANCE THERAPY WITH LOW DOSE THALIDOMIDE, DEXAMETH-
ASONE AND CLARITHROMYCIN (BLT-D) FOLLOWING AUTOLOGOUS
TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM)
Holmberg, L.1,2, Gooley, T.1, Becker, P.1,2, Maloney, D.1,2,
Bensinger, W.1,2 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA
Since relapse remains amajor problem after ASCT forMM, inves-
tigators have looked at the role of maintenance therapy post trans-
plant. It is not yet established which maintenance regimen is best
or the optimal duration for therapy.M. Coleman et al (Leuk&Lym-
phoma 43: 1777, 2002), pioneered a well tolerated regimen of BLT-
D with high CR/PR rates (93%) in MM patients. These results sug-
gested that BLT-D regimen may have a role as maintenance therapy
after ASCT.Twenty-seven patients (stage II, n-8; stage III, n5 19 by
Durie-Salmon criteria) were treated. Before ASCT, 52% had re-
ceived Thalidomide, 26% had received VAD, and 37% were treated
withmore than one regimen (range 2-4) prior tomobilization of stem
cells. At the time of ASCT, 20% were in CR/near CR. Following
ASCT, all patients received conditioning with melphalan 200mg/m2. After recovery from conditioning toxicity, between 30-120
days post ASCT (median 101 days (range 33-119), patients were
treated with Clarithromycin 250 mg po bid, dexamethasone 20 mg
po weekly, and thalidomide beginning dose 50 mg po daily days 1-
14, then increased to 100 mg po daily. After one year of combination
therapy, dexamethasone andClarithromycin were stopped. Thalido-
mide was given as long as tolerated until disease progression. Aspirin
and low dose coumadin were used as DVT prophylaxis. Six patients
(22%) discontinued thalidomide for progressive disease.Neuropathy
was the most common toxicity: 12 patients (44%) stopped because of
unimproved$ grade 2 toxicity and 7 (26%) required dose reduction
of thalidomide. One patient stopped therapy because of rash.Median
time to stoppingThalidomidewas 13.5months (range 6-42months).
Nine patients (33%) required dose reduction of dexamethasone. The
number of infections included: pneumonia (n5 3), upper respiratory
viral infection (n5 2), sinusitis (n5 1), and bronchitis (n5 3). Seven
patients have died due to: infection (n 5 1), MM (n 5 5), and com-
plications of second ASCT (n 5 1). As of 7/12/10, 20 patients
(74%) are alive and 13 (48%) are alive without disease progression.
Median follow-up is 59.5 months (38-73 months). In summary,
BLT-D can be given post ASCT. Peripheral neuropathy was the
most common significant toxicity that required patients to stop ther-
apy. With a median follow-up of 59.5 months from ASCT, 48% of
the patients are alive without evidence of disease progression and
74%are alive. Randomized studies to compare onemaintenance reg-
imen to another are needed post ASCT.268
MAINTENANCE THERAPYWITH LENALIDOMIDE, DEXAMETHASONE AND
CLARITHROMYCIN (BIRD) FOLLOWING AUTOLOGOUS TRANSPLANT
(ASCT) FOR MULTIPLE MYELOMA (MM)
Holmberg, L.1,2, Gooley, T.1, Becker, P.1,2, Bensinger,W.1,2 1FredHutch-
inson Cancer Research Center, Seattle, WA; 2University of Washington,
Seattle, WA
Since relapse remains a major cause for treatment failure after
ASCT for MM, the role of maintenance therapy has been studied.
Neither the best maintenance regimen nor optimal duration of ther-
apy post ASCT has been established. Niesvizky R et al (Blood 111:
1101-09, 2008) reported on the efficacy of BIRD as front-line ther-
apy for MM, with 90% objective response rate and manageable tox-
icities. Thus, it seemed reasonable to study such a regimen as
maintenance therapy post ASCT. Thirty-one patients (Stage I/II,
n5 13 and stage III, n5 18 by Durie-Salmon criteria) were treated.
Before ASCT, 81% received Thalidomide, 23% Lenalidomide, and
45% Bortezomib; 58% were treated with . 1 regimen (range 1-4)
prior to mobilization. Cytogenetic abnormalities included: poor
prognosis (23%), del13 by FISH (13%), t11,14 (10%), and tris 11/
11q (10%). PBSC were collected in 80% of patients off chemother-
apy/growth factor. At ASCT, 42% of patients were in PR, 6.5% had
SD, and 6.5% had progressive disease. All patients were conditioned
with melphalan 200mg/m2; one patient was treated after planned
tandem. At median of 113 days (range 49-133) and after recovery
from acute toxicity of ASCT, patients were treated with Clarithro-
mycin 250 mg po bid, Dexamethasone 20 mg po weekly, and Lena-
lidomide 25 mg po daily day 1-14 every 21 day cycles. After one year
of combination therapy, dexamethasone was tapered off and Clari-
thromycin was stopped. Lenalidomide was continued as long as tol-
erated until disease progression. All patients were treated daily with
coated aspirin (325 mg) for DVT prophylaxis. One patient devel-
oped DVT/PE. Five patients stopped therapy for disease progres-
sion and 11 stopped for significant toxicity (protracted . 30 days
peripheral neuropathy grade 3 (n 5 2), VZV/PCP/viral pneumonia
(n5 3), protracted neutropenia (n5 3), MDS 5q (n5 1), cellulitis (n
5 1), and leukocytic vasculitis (n 5 1)). Peripheral neuropathy and
neutropenia were most common non-infectious toxicities. As of 9/
2010, all patients remain alive and twenty patients (65%) remain
alive without disease progression; with median follow-up of 33
months (range 20-45) from transplant. In summary, BIRD can be
given post ASCT. Peripheral neuropathy and neutropenia are
most common non-infectious toxicities. With median follow-up of
33 months, all patients remain alive and 65% remain alive without
S252 Poster Session Iprogressive disease. A randomized trial comparing different mainte-
nance regimens post ASCT is needed to determine best regimen.269
PROGNOSTIC SIGNIFICANCE OF PRE-TRANSPLANTATION FDG-PET/CT IN
PATIENTS WHO UNDERGO ALLOGENIC STEM CELL TRANSPLANTATION
FOR LYMPHOMA
Kudo, M.1, Tada, K.1, Tajima, K.1, Asakura, Y.1, Kim, S.-W.1,
Hiramoto, N.1, Ueno, N.1, Mori, S.-I.1, Tanosaki, R.1, Heike, Y.1,
Yano, T.2, Takaue, Y.1, Fukuda, T.1 1National Cancer Center Hospital,
Tokyo, Chu-o-Ku, Japan; 2Tokyo National Medical Center, Tokyo,
Meguro-ku, Japan
A positive scan in pre-transplantation fluorine-18 fluorodeoxyglu-
cose positron emission tomography (FDG-PET) has been shown to
be associated with a poor prognosis in patients with malignant lym-
phoma (ML) undergoing high-dose chemotherapy followed by au-
tologous stem cell transplantation (SCT). However, it remains
unclear with allogeneic SCT. Therefore, we conducted a retrospec-
tive analysis of 52 consecutive patients with ML who had undergone
FDG-PET scan before allogeneic SCT at our institution from Jan-
uary 2005 to July 2010. The median age was 52 years (range: 20-64),
and the median follow-up after allogeneic SCT was 475 days (range:
46-1553). Twenty-three patients were FDG-PET-negative and
twenty-nine were positive with a median SUV of 7.23 (range: 2.7-
17.82). Nine indolent lymphomas and 14 aggressive lymphomas
were PET-negative, while 14 indolent and 15 aggressive lymphomas
were PET-positive (p5 0.52). Among the PET-negative patients, 5
and 18 received myeloablative and reduced-intensity conditioning
respectively. On the other hand, 9 of the 20 PET-positive patients
received myeloablative conditioning (p 5 0.54). Other characteris-
tics (age, serum LDH, extranodal sites, donor source) were not sig-
nificantly different between the PET-positive and PET-negative
groups. Although the cumulative incidence of progression at 1 year
was lower in the PET-negative patients, there was no statistical sig-
nificance (15% vs 31%, p5 0.35). Although overall survival (OS) and
progression-free survival (PFS) rate at 3 years after allogeneic SCT
were higher in the PET-negative patients, there were no statistical
significances (OS 83% vs 58%, p 5 0.21; PFS 67% vs 53%, p 5
0.22). Median survival time was not reached in either PET-negative
or -positive patients.A multivariate analysis by Cox regression anal-
ysis showed that high serum LDH was associated with an increased
risk of poor OS (HR 4.11, 95% CI 1.23-13.78, p 5 0.02). On the
other hands, a positive PET findings did not significantly affect
the OS (HR 1.80, 95% CI: 0.46-6.96, p 5 0.40). In conclusion,
ours study suggested that, in contrast to the setting of autologous
SCT, a positive pre-transplant PET finding may not be a predictor
of poor OS in patients with lymphoma who underwent allogeneic
SCT.270
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMA
PATIENTS: THE IRANIAN EXPERIENCE
Alimoghaddam, K., Jahani, M., Mousavi, S.A., Bahar, B., Iravani, M.,
Hamidieh, A.A., Jorjani, H., Jalali, A., Ghavamzadeh, A. Tehran
University of Medical Sciences, Tehran, Tehran, Islamic Republic of Iran
Background: Autologous hematopoietic stem cell transplantation
(HSCT) is a potentially curative treatment in patients with lym-
phoma including Hodgkin’s disease (HD) and non-Hodgkin’s lym-
phoma (NHL).
Patients and Methods: 416 lymphoma patients (269 male and 147
female) with a median age of 25 years (range: 12-60 years) in 204HD
patients and amedian age of 33 years (range: 8-62 years) in 206NHL
Patients had received HSCT in our center from January, 1992
through October, 2010. The most common subtypes of NHL Pa-
tients were 86 (42%) diffuse large B-cell lymphoma and 35 (17%)
lymphoblastic lymphoma. The most common status of disease be-
fore transplantation was First and second complete remission in
NHL patients and second complete remission in HD patients.
The sources of hematopoietic stem cells for lymphoma patients
were 397 peripheral blood (194 NHL, 203 HD), 16 bone marrow(10 NHL, 6 HD) and 3 patients with combined Peripheral blood
and bone marrow (2 NHL, 1 HD).
Results:Themedian time (days) to AbsoluteNeutrophil Count.5
0.5 * 109/L was114 in HD and113 in NHL patients. The median
time (days) to platelet count.5 20 * 109/L was122 inHD and118
in NHL patients. The median follow up time was 14 months. The
three years, disease-free survival (DFS) for HD and NHL patients
was 78.8% and 63.3%, recpectively. The three years overall survival
(OS) for HD and NHL patients was 91.8% and 71.4 %. Acute and
chronic GVHD occurred in 16 (53.3%) and 7 (23.3%) of NHL
patients with Allogeneic HSCT. The three years, DFS for autolo-
gous and allogeneic transplantation in NHL patients was 64.9%
and 56.3% (p 5 0.543).The three years, OS for autologous and
allogeneic transplantation in NHL patients was 72.2% and 68.5
%, (p 5 0.843).
Conclusion:Our results confirm that autologousHSCT is a suitable
treatment in patients with NHL and relapsed HD. More impor-
tantly, there is no significant difference between autologous and
allogeneic HSCT in NHL patients.271
AUTOLOGOUS STEM CELL TRANSPLANTATION AS FRONT LINE THERAPY
DOES NOT IMPROVE THE OUTCOME OF HIGH RISK AGGRESSIVE NON-
HODGKIN’S LYMPHOMA: A SINGLE CENTER STUDY
Won, J.-H., Yun, J., Kim, H.J., Kim, K.H., Kim, S.-H., Lee, S.-C.,
Kim, H.J., Bae, S.B., Kim, C.K., Lee, N.S., Lee, K.-T., Park, S.K.,
Hong, D.S., Park, H.S. Soonchunhyang University Hospital, Seoul, Korea
Background:The role of high dose therapy (HDT) followed by au-
tologous stem cell transplantation (ASCT) as front-line therapy in
the high risk aggressive non-Hodgkin’s lymphoma (NHL) patients
is still a matter of debate, but several studies demonstrated the effi-
cacy of HDT. Since Rituximab added to CHOP chemotherapy,
OS and PFS were significantly improved. Therefore, we analysed
to compare conventional chemotherapy with HDT followed by
ASCT in aggressive NHL.
Patients andMethods:We retrospectively reviewed themedical re-
cords of 357 patients with primary diagnosed aggressive NHL from
January 2002 to December 2009. Among them, we select patients
who achieved to complete or partial remission after first induction
chemotherapy or had $ 3 International Prognostic Index (IPI)
scores or stage III, IV. Among 357 patients, 42 patients younger
than 65 years were enrolled and categorized to two groups: conven-
tional chemotherapy group (n 5 33, 79%) and HDT followed by
ASTC group (n 5 9, 21%).
Results: The median age at the time of diagnosis was 46 years
(range, 15-64). Diffuse large B-Cell lymphoma (DLBLC, 48%),
T-cell lymphoma (38%), lymphoblastic lymphoma (7%) was in-
cluded. The proportion of Rituximab including regimen for induc-
tion chemotherapy were 49%. The five-year overall survival rate
was not significantly different between two groups (72% in chemo-
therapy group vs. 70% in HDT group, P5 0.73). And the estimated
progression free survival at five years was not significantly different
between two groups (51% in chemotherapy group vs. 53% in
HDT group, P 5 0.63).
Conclusion: The efficacy of HDT followed by ASTC during first-
line treatment in patients with aggressiveNHLdoes not improve the
outcome and should be evaluated in randomized trials.272
TRANSPLANT OUTCOMES IN MULTIPLE MYELOMA PATIENTS YOUNGER
VERSUS OLDER THAN 60 YEARS OF AGE IN THE ERA OF NEWER
TARGETED AGENTS
Naik, S., Shope, D., Albright, C., Graham, R., Levitan, D., Zamkoff, K.,
D’Agostino R Jr., Jr., Hurd, D. Wake Forest Hospital Medical Center,
Winston-Salem, NC
Introduction: Various newer agents are available recently and revo-
lutionized treatment ofmyeloma and are usedwith intention to over-
come the adverse influence of cytogenetic abnormalities. We were
